We have performed an in-depth examination of the genomic profiles of primary breast and ovarian tumors in patients with germline BRCA1 and BRCA2 mutations with the goal of identifying correlates of therapeutic response, using two data sets. The gene discussed is BRCA1; the disease is ovarian neoplasm.